Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Projected Accrual
Outline
Trial Contact Information

Alternate Title

Celecoxib and/or EKB-569 in Preventing Oral Cancer in Patients With Oral Leukoplakia

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs No phase specified Prevention Approved-not yet active 18 and over NCI MDA-2003-0824 MDA-NRH-2003-16

Objectives

Primary

1. Compare the incidence of oral cancer in patients with aneuploid premalignant lesions in the oral cavity treated with celecoxib and EKB-569 vs celecoxib alone vs EKB-569 alone vs placebo.

Secondary

1. Correlate the size, number, and appearance of oral premalignant lesions with cancer risk in patients treated with these regimens.
2. Compare the toxicity of these regimens in these patients.
3. Correlate molecular markers with oral cancer development in patients treated with these regimens.

Entry Criteria

Disease Characteristics:

• Diagnosis of oral aneuploid premalignant lesion within the past 3 months
  • Dysplastic white or red patches in the oral cavity with DNA aneuploidy determined by high resolving image cytometry



• Must have sufficient lesion to biopsy



• No prior or active head and neck cancer or lung cancer



• No known metastases to the head and neck area from other tumors

Prior/Concurrent Therapy:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• No concurrent adrenocorticosteroids

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• More than 3 months since prior participation in any other experimental therapy study
• More than 14 days since prior routine non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin > 100 mg/day
• No concurrent fluconazole, lithium, warfarin, or NSAIDs
  • Concurrent aspirin ≤ 100 mg/day allowed

Patient Characteristics:

Age

• 18 and over

Performance status

• ECOG 0-1

  OR

• Karnofsky 80-100%

Life expectancy

• Not specified

Hematopoietic

• WBC > 3,000/mm³
• Platelet count > 125,000/mm³
• Hemoglobin normal

Hepatic

• AST and ALT ≤ 1.5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 1.5 times ULN
• Bilirubin ≤ 1.5 times ULN

Renal

• Creatinine ≤ 1.5 times ULN
• Calcium normal
• Glucose normal
• Phosphate normal
• Urea normal
• Uric acid normal

Cardiovascular

• No active coronary artery disease
• No unstable angina
• No uncontrolled hypertension
• No myocardial infarction within the past 6 months
• No congestive heart failure within the past 6 months
• No cardiac arrhythmia requiring antiarrhythmic therapy

Pulmonary

• No asthma
• No active chronic obstructive pulmonary disease
• No other moderate to severe respiratory illness within the past 6 months

Gastrointestinal

• No history of gastrointestinal bleeding or perforation
• No peptic ulcer disease without bleeding

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No known hypersensitivity to NSAIDs, sulfonamides, or cyclo-oxygenase-2 inhibitors
• No medical or psychological condition or other reason that would preclude study participation
• Sodium normal
• Potassium normal
• Magnesium normal
• CO₂ content normal
• Chloride normal
• No other cancer within the past 2 years except nonmelanoma skin cancer

Projected Accrual

A total of 360 patients (90 per treatment arm) will be accrued for this study within 2-3 years.

Outline

This is a randomized, placebo-controlled, double-blind, multicenter study. Patients are stratified according to Nordic country of participation and cardioprotective acetylsalicylic acid use (yes vs no). Patients are randomized to 1 of 4 treatment arms.

• Arm I: Patients receive oral celecoxib twice daily and oral placebo once daily.



• Arm II: Patients receive oral EKB-569 once daily and oral placebo twice daily.



• Arm III: Patients receive oral celecoxib twice daily and oral EKB-569 once daily.



• Arm IV: Patients receive one oral placebo twice daily and another oral placebo once daily.

In all arms, treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.

Patients are followed at every 3 months for 2 years and then every 6 months for 5 years.

Disclaimer

The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Trial Contact Information

Trial Lead Organizations

University of Texas - MD Anderson Cancer Center

Scott Lippman, MD, FACP, Principal investigator		Ph: 713-745-3672; 800-392-1611

Back to Top